Blog

Should You Take Testosterone? Here’s What the Evidence Says

By Harveen Kaur, MD
Internal Medicine Physician

Overview

If you spend enough time in wellness culture, testosterone (T) starts to feel like a universal upgrade. Men in their 30s through 60s hear a “normal but on the low end” level is why they feel flat at work or slow in the gym. Women are told microdosing will sharpen focus, protect muscle, and restore energy, often around perimenopause.

I see two problems with how medicine looks at testosterone use. First, we rely on rigid lab cutoffs and outdated package inserts that end up leaving real symptoms unaddressed. At the same time, some cash-pay clinics hand out prescriptions for vague symptoms based on a single borderline blood test and ignore the very real physiological trade-offs.

T is useful and can be the right therapy for some people. It is not a catch-all fix. Even when you feel better in the short term, using it carries real risk.

Key takeaways

QuestionAnswer
What does testosterone treat?In men with confirmed low T, it improves sex drive, erections, bone density (though it hasn't been shown to prevent fractures), and mild anemia, with modest gains in muscle.[1, 2, 10, 20] In postmenopausal women with low desire that causes distress, it improves desire, arousal, and orgasm.[5, 12]
Will it fix low energy, mood, or brain fog?Not reliably. In a year-long trial in older men with low T, energy and memory didn't improve, and the mood benefit was small. In women, there's no clear evidence it helps mood, wellbeing, or memory.[10, 11, 12]
How is low testosterone diagnosed in men?Symptoms plus low levels on two separate early-morning tests. About 30% of men with a low first result are normal on the second.[1, 14]
Can a blood test show whether a woman needs it?No. Testosterone levels don't track with sexual desire. Levels are checked to keep treatment within the female range.[5, 6]
What are the main risks?In men, higher red blood cell counts, higher blood pressure, and in the largest trial, more blood clots in the lungs and more atrial fibrillation. In women, acne, hair growth, and voice changes when the dose runs too high.[3, 4, 5]
Does it affect fertility?Yes. Testosterone suppresses sperm production for months, so men who want children soon need a different approach.[2]

What testosterone actually treats

For men with confirmed hypogonadism (symptoms + consistently low AM levels): It improves sexual desire, erectile function, bone density, and mild unexplained anemia. Gains in lean muscle and loss of fat are modest but real.[1, 2] Bone density goes up, but in the largest trial, men on testosterone had more fractures than men on placebo, possibly for other reasons such as increased activity level.[20]

For postmenopausal women with hypoactive sexual desire disorder (HSDD)*: It improves desire, arousal, and orgasm.[5, 12]

That is the core of what the evidence supports.

It does not reliably fix energy, cognition, depression, blood sugar, or cholesterol in men,[2, 10, 11] or mood, wellbeing, cognition, bone, or muscle at physiologic doses in women.[5, 12] The largest trial in older men improved sexual function but not energy or thinking; any mood benefit was small.[10, 11] The same pattern held in women.[12]

Testosterone does build muscle, and the amount depends on the dose.[16] Men with true deficiency see modest gains.[1] In women, trials at normal female doses haven't shown muscle gains.[5] In one study, a dose raised T about fivefold added about 2% lean mass in 10 weeks.[7] If a woman on T notices her muscles getting bigger, that can be a sign the dose has drifted too high.

*HSDD is a persistent lack of sexual desire that causes personal distress and has lasted at least 6 months, not better explained by another issue.

FDA Approval and When It Matters

Medication indications do not end with FDA approval, but knowing what the FDA has approved helps you avoid two traps: rejecting legitimate off-label care, or accepting unmonitored protocols with no clinical backing.

The FDA removed outdated heart attack warnings from the labels after the TRAVERSE trial and has approved more than a dozen testosterone products for men.[3, 4] In June 2026, HHS asked the FDA to go further, including removing the label's limitation on age-related low testosterone. As of this writing, those changes are still pending.[21] Even so, we routinely use off-label options like clomiphene and hCG† when a man wants to protect fertility, because these raise the body's own testosterone without shutting down sperm production.[2]

Women face the opposite problem. The United States still does not have an FDA-approved testosterone product for us despite Australia, New Zealand, and the UK having already made moves here.[17, 18, 19] The evidence is solid: more than two decades of randomized trials support testosterone for low desire after menopause, and the major endocrine and menopause societies also endorse it.[5] Physicians can prescribe it off-label when women have those symptoms.

†Clomiphene is a pill that signals the brain to tell the testes to make more of their own testosterone. hCG is an injection that mimics a natural pregnancy hormone and directly stimulates the testes.

Common myths about testosterone levels

Several persistent misconceptions still drive both under- and over-treatment:

“My total T is normal, so I'm fine.”

Not necessarily. Most testosterone rides on a carrier protein called SHBG. Only the free portion is active. SHBG shifts with age, obesity, thyroid status, oral estrogen, and insulin resistance. The same total number can mean very different things in two people. When SHBG is off, free testosterone tells the real story.[1]

“One low reading means low T.”

Testosterone peaks in the morning and dips with illness, poor sleep, hard training, or dieting. Guidelines require two early-morning fasting draws plus symptoms before diagnosing deficiency. Roughly 30 percent of men with a low first result are normal on the second test.[1, 14]

“Low-normal means low.”

It does not. What matters is the combination of consistent levels and real symptoms. If you're in this range but you're wondering about starting treatment because of your symptoms, that's a valid concern worth bringing up.[1, 2]

“T drops with age, so most men over 40 need it.”

Levels do drift down with age, but much of that drop tracks with weight gain and chronic illness. The Endocrine Society advises against treating for a low number alone.[1, 15]

“A woman's testosterone level shows whether she needs it.”

No blood level separates women with low desire from those without it.[5, 6, 13] We still check levels to make sure they are not already high and to keep treatment inside the female range.

“Higher is better.”

Above the normal range, men keep adding muscle, but sexual function, mood, and thinking don't improve any further, and the risks keep climbing.[1, 5, 16]

When is T the right choice

It makes sense for men who have treatable symptoms, confirmed with low morning levels on repeat testing. It also makes sense for postmenopausal women with HSDD whose estrogen and progesterone needs are already addressed.[1, 2, 5]

It's not a good fit if your main concerns are fatigue, brain fog, mood, or weight without a confirmed deficiency. Starting it is not the next best step if you have only one low reading or a slow age-related decline. It should also be avoided for men who want children in the near term, because exogenous testosterone suppresses sperm production for months.[2]

If you feel tired, foggy, or flat, those symptoms are real and worth getting to the bottom of. Poor sleep, stress, weight gain, heavy drinking, and chronic illness can drain energy and mood while also lowering testosterone, so the two often show up together.[1, 15] Treating those usually does more for how you feel than treating the number.

The real risks

Testosterone raises red-blood-cell counts, can increase clot risk, and can also raise blood pressure.[4] The TRAVERSE trial was reassuring on heart attacks and strokes, but men on testosterone had more pulmonary emboli and more atrial fibrillation than men on placebo.[3]

In women, trouble usually starts when the dose drifts above the female range. Acne and extra hair growth can occur but will fade when the dose comes down. Scalp hair thinning, a deeper voice, and clitoral enlargement can be permanent. That's why pellets (which release unpredictable amounts for months and cannot be adjusted) and oral testosterone (which worsens cholesterol) are poor choices.

Long-term data in women have a ceiling. Most trials ran about two years. We still don't know what 10 or 20 years of use means for heart disease or breast cancer.[5, 12]

How we approach it at SONATA

Every member's baseline panel already includes fasting insulin and HOMA-IR so we can see whether metabolic health is pulling testosterone down. When hormone testing is appropriate we check total testosterone, free testosterone, and SHBG together. We talk about sleep, weight, and lifestyle habits so the context for each concern is still present.

If we start treatment, we agree in advance on a target range, a recheck date, and a clear stopping point if it's not helping. That includes tracking red-blood-cell counts. In women, we check a T level a few weeks in and periodic re evaluation about whether we should continue or not.[1, 5]

For women, we know the system is lagging behind both the science and the needs our patients have. In the meantime, we use FDA-approved testosterone gels at a much lower dose than men use, an approach the global consensus supports, and keep levels in the female range.[5]

If you're thinking about or have already started T, bring up:

  1. What level are we aiming for?
  2. When will we recheck?
  3. When would we stop?

Those three questions separate careful, evidence-based care from all the noise.

Frequently asked questions

References

  1. Bhasin S, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744.
  2. Mulhall JP, et al. Evaluation and Management of Testosterone Deficiency: AUA Guideline. J Urol. 2018;200(2):423-432.
  3. Lincoff AM, et al. Cardiovascular Safety of Testosterone-Replacement Therapy (TRAVERSE Trial). N Engl J Med. 2023;389(2):107-117.
  4. U.S. Food and Drug Administration. FDA Issues Class-Wide Labeling Changes for Testosterone Products. February 28, 2025.
  5. Davis SR, et al. Global Consensus Position Statement on the Use of Testosterone Therapy for Women. J Clin Endocrinol Metab. 2019;104(10):4660-4666.
  6. Wang Y, et al. Associations Between Testosterone and Pre-Androgens and Sexual Function: Findings From the Australian Women's Midlife Years Study. Fertil Steril. 2026;126(3).
  7. Horwath O, et al. Fiber Type-Specific Hypertrophy and Increased Capillarization in Skeletal Muscle Following Testosterone Administration in Young Women. J Appl Physiol. 2020;128(5):1240-1250.
  8. Clemesha CG, et al. “Testosterone Boosting” Supplements Composition and Claims Are Not Supported by the Academic Literature. World J Mens Health. 2020;38(1):115-122.
  9. U.S. Food and Drug Administration. FDA Public Workshop: Testosterone Use in Menopausal Women (Docket No. FDA-2026-N-5479). September 17, 2026.
  10. Snyder PJ, et al. Effects of Testosterone Treatment in Older Men. N Engl J Med. 2016;374(7):611-624.
  11. Resnick SM, et al. Testosterone Treatment and Cognitive Function in Older Men With Low Testosterone and Age-Associated Memory Impairment. JAMA. 2017;317(7):717-727.
  12. Islam RM, et al. Safety and Efficacy of Testosterone for Women: A Systematic Review and Meta-Analysis of Randomised Controlled Trial Data. Lancet Diabetes Endocrinol. 2019;7(10):754-766.
  13. Wierman ME, et al. Androgen Therapy in Women: A Reappraisal: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2014;99(10):3489-3510.
  14. Brambilla DJ, et al. Intraindividual Variation in Levels of Serum Testosterone and Other Reproductive and Adrenal Hormones in Men. Clin Endocrinol (Oxf). 2007;67(6):853-862.
  15. Wu FC, et al. Hypothalamic-Pituitary-Testicular Axis Disruptions in Older Men Are Differentially Linked to Age and Modifiable Risk Factors: The European Male Aging Study. J Clin Endocrinol Metab. 2008;93(7):2737-2745.
  16. Bhasin S, Woodhouse L, Casaburi R, et al. Testosterone Dose-Response Relationships in Healthy Young Men. Am J Physiol Endocrinol Metab. 2001;281(6):E1172-E1181.
  17. Therapeutic Goods Administration. AndroFeme 1 (testosterone 1% cream) Product Information. ARTG 324274. First approved November 23, 2020.
  18. Medsafe. AndroFeme 1 data sheet. First approved April 24, 2025.
  19. Lawley Pharmaceuticals. MHRA approves testosterone cream for UK postmenopausal women. Marketing authorisation July 25, 2025. Also listed by NHS Wales (AWTTC) with the HSDD indication.
  20. Snyder PJ, et al. Testosterone Treatment and Fractures in Men with Hypogonadism. N Engl J Med. 2024;390(3):203-211.
  21. U.S. Department of Health and Human Services. HHS Announces Requested Updates to Testosterone Therapy Product Labels. June 18, 2026.

Ready to get started?

Join Now